PT - JOURNAL ARTICLE AU - Maria Liza Lindenberg AU - Esther Mena AU - Ismail Turkbey AU - Stephen Adler AU - Anita Ton AU - Yolanda McKinney AU - Juanita Weaver AU - Philip Eclarinal AU - Gideon Kwarteng AU - Anna Couvillon AU - Deborah Citrin AU - Peter Pinto AU - William Dahut AU - Martin Pomper AU - Peter Choyke TI - A pilot study of 18F-DCFBC PET/CT imaging for tumor detection in prostate cancer patients with biochemical relapse after definitive treatment DP - 2016 May 01 TA - Journal of Nuclear Medicine PG - 1555--1555 VI - 57 IP - supplement 2 4099 - http://jnm.snmjournals.org/content/57/supplement_2/1555.short 4100 - http://jnm.snmjournals.org/content/57/supplement_2/1555.full SO - J Nucl Med2016 May 01; 57 AB - 1555Objectives 18F DCFBC is a low molecular weight, urea based small molecule targeting an external binding domain of PSMA. Found in almost all prostate cancers, PSMA is a promising target for imaging and therapy. Patients with biochemical recurrence after definitive therapy for prostate cancer are frequently treated empirically with pelvic irradiation and accurate localization of disease could enable more targeted therapy with decreased morbidity related to treatment. We aimed to evaluate the utility of using 18F DCFBC, for tumor detection in patients with biochemical relapse of prostate cancer. Methods This is a prospective IRB-approved study including 34 prostate cancer patients (65 ± 6 yo, range 57 - 82 yo), Gleason score at diagnosis was 7 [range 6 to 9], with rising PSA after total prostatectomy (n = 30) or after salvage radiation therapy (n = 4). Median PSA= 2.0 ± 7.5 ng/ml [range 0.22 - 37.19]. All patients underwent 18F DCFBC PET/CT imaging [average dose: 279.1 MBq, ranged 222 - 296 MBq] at 1 h and 2 hours after intravenous injection. Histology (when available) was used to correlate PET findings. Results Of the total 34 patients analyzed, 18F DCFBC scans were positive in 9 (median PSA 3.33 ng/ml, range 1.31 - 37.19), indeterminate in 12 (median PSA 1.94 ng/ml, range .39 - 11.26) and negative in 13 patients (median PSA 1.39 ng/ml, range .22 - 5.66). Positive lesions were detected in nodes and soft tissues of the pelvis in 3 patients, and outside the pelvis in 6 patients. Histologic confirmation was provided in 7 patients. There was 1 true positive, 1 false positive, and 1 false negative finding. The indeterminate group had 3 negative biopsy results and 1 positive biopsy. Conclusions 18F DCFBC shows promise as an imaging tool for patients with biochemically recurrent prostate cancer after definitive treatment. Further analysis compared to multiparametric MRI and more histologic samples will be helpful for this group, especially in the clinically important range of low PSA values which may further influence clinical management.